In 2026, several critical phase 3 readouts could reshape the landscape of their respective indications. We're watching eight upcoming catalysts, with pivotal trials scheduled for late 2026 and into 2027. Understanding these clinical trial results can significantly influence investment decisions.
The full Phase 2 and Phase 3 readouts to watch
| Date | Ticker | Drug | Indication | Phase | PoA |
|---|---|---|---|---|---|
| 2027-04 | CGTX | CT1812, Placebo (-7% run-up) | Early Alzheimer's Disease | PHASE2 | n/a |
| 2027-04 | MNOV | MN-166, placebo (+10.2% run-up) | Amyotrophic Lateral Sclerosis | PHASE2 | n/a |
| 2026-12-31 | MNOV | MN-001, MN-001 placebo (+10.2% run-up) | Diabetes Mellitus, Type 2 | PHASE2 | n/a |
| 2026-09-28 | MLTX | Sonelokimab | Hidradenitis Suppurativa | PHASE3 | n/a 🔒 |
| 2027-02-04 | MLTX | Sonelokimab, Placebo | Arthritis, Psoriatic | PHASE3 | n/a 🔒 |
| 2026-09 | CORT | Miricorilant (Cohort A), Placebo (Cohort A), Miricorilant (Cohort B), Placebo (Cohort B) | Nonalcoholic Steatohepatitis (NASH) | PHASE2 | n/a 🔒 |
| 2026-12 | CORT | relacorilant | Cushing Syndrome | PHASE2 | n/a 🔒 |
| 2028-01-26 | REGN | BNT116, Cemiplimab | Advanced Non-Small Cell Lung Cancer | PHASE2 | n/a 🔒 |
| 2026-12 | GILD | anitocabtagene-autoleucel | Multiple Myeloma | PHASE2 | n/a 🔒 |
| 2028-07 | GILD | Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib | Multiple Myeloma | PHASE3 | n/a 🔒 |
| 2026-09-27 | BIIB | Litifilimab, Placebo | Lupus Erythematosus, Systemic | PHASE3 | n/a 🔒 |
CGTX's CT1812: A Phase 2 Readout for Early Alzheimer's Disease
CGTX plans to release phase 2 results for CT1812 in April 2027, targeting Early Alzheimer's Disease. This follows a -7% run-up, signaling possible market skepticism or profit-taking. CT1812 targets the toxic effects of amyloid-beta, a key factor in Alzheimer's pathology. Positive results could mean a significant upside for CGTX, but disappointing outcomes might worsen the current downward trend. We'll be watching insider activity and market sentiment closely as this readout nears.
MNOV's MN-166: Insights on Amyotrophic Lateral Sclerosis
MNOV's MN-166 phase 2 readout is also set for April 2027, aimed at treating Amyotrophic Lateral Sclerosis (ALS), a condition lacking many treatment options. The stock has seen a 10.2% run-up, hinting at investor optimism. Known for its neuroprotective properties, MN-166 could offer a new treatment avenue. However, a failure could sharply drop MNOV's stock price. We'll examine the trial's efficacy and safety, crucial for this vulnerable patient group.
MNOV's MN-001: A Phase 2 Readout for Type 2 Diabetes
MNOV is gearing up for another phase 2 readout with MN-001 on December 31, 2026, targeting Type 2 Diabetes. Following a 10.2% run-up, investors seem to anticipate positive outcomes. MN-001 aims to improve insulin sensitivity, crucial for diabetes management. The competitive diabetes therapy market makes these results pivotal. A positive readout could elevate MNOV's market position, while adverse results could lead to a pipeline reassessment. We will monitor the risk of underperformance as the trial date approaches.
Gated Items: A Broader Look at Upcoming Phase 3 Readouts
Beyond immediate phase 2 readouts, eight gated items offer a broader view of potential phase 3 results. MLTX's Sonelokimab will report results for Hidradenitis Suppurativa on September 28, 2026. Anticipation is high due to the lack of effective treatments for this condition. CORT is preparing a phase 3 readout on Miricorilant for Nonalcoholic Steatohepatitis (NASH) in September 2026, a growing concern with the rise of metabolic syndrome. These trials could significantly influence company valuations. We'll assess the potential market impact as these readouts approach.
The Importance of Timing in Phase 3 Readouts
Timing is crucial for phase 3 readouts. BIIB's Litifilimab readout for Systemic Lupus Erythematosus is set for September 27, 2026, potentially aligning with broader market movements. Lupus treatments have historically struggled to show efficacy, making this data critical. The timing of these readouts often impacts stock performance, as investors react to both results and the market context. We'll watch market sentiment and any insider trading activity that might signal investor confidence or doubt.
Risk Factors Associated with Phase 3 Readouts
Investing around phase 3 readouts carries significant risk. GILD's upcoming readouts for anitocabtagene-autoleucel in Multiple Myeloma in December 2026 and January 2028 have substantial risk-reward profiles. Success might boost stock prices, but negative results could severely impact investor confidence. The complexity of oncology trials raises the stakes. We will evaluate efficacy and safety data to gauge these candidates' long-term viability. Understanding these risks is essential for informed investment decisions.
The bottom line
Staying informed about these pivotal phase 3 readouts will be key to making sound investment decisions.
Frequently asked questions
What are phase 3 readouts?
Phase 3 readouts are results from late-stage clinical trials assessing a drug's efficacy and safety before regulatory approval.
Why are these readouts important for investors?
They provide critical insights into a drug's potential market success and can significantly influence stock prices.
How do run-up percentages affect investment decisions?
Run-up percentages indicate market sentiment; a positive run-up suggests optimism, while a negative run-up may signal caution.
What risks are associated with investing based on clinical trial results?
Primary risks include potential negative results, which can lead to stock price declines and impact investor confidence.